GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (FRA:4A1) » Definitions » Valuation Rank

Cereno Scientific AB (FRA:4A1) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Cereno Scientific AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cereno Scientific AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cereno Scientific AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (FRA:4A1) » Definitions » Valuation Rank
Comparable Companies
XSAT:EQL OSTO:ENZY OSTO:ORX OSTO:ALZCUR OSTO:MOB OSTO:ERMA OSTO:VIVE XSAT:PMED XSAT:ODI XSAT:DICOT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CRNO B:Sweden
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Website
https://www.cerenoscientific.se
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.